查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年代謝治療市場預測：按治療類型、藥物類別、配銷通路、應用和地區進行的全球分析
市場調查報告書
商品編碼
1383471

2030 年代謝治療市場預測：按治療類型、藥物類別、配銷通路、應用和地區進行的全球分析

Metabolism Drugs Market Forecasts to 2030 - Global Analysis By Therapy Type, Drug Class, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球代謝治療市場規模為 174.5 億美元，預計預測期內年複合成長率為 8.4%，到 2030 年將達到 308.5 億美元。

代謝藥物是一種旨在影響或調節體內代謝過程的藥物。它也被稱為代謝調節劑。根據特定藥物及其治療的醫療狀況，可以預期會產生不同的效果。代謝調節劑可以改善心血管健康，提高運動成績，提高能量水平，降低膽固醇水平，並有助於體重管理。

根據世界衛生組織 (WHO) 統計，2016 年約有 6.5 億人患有肥胖症，預計到 2030 年這一數字將增加四倍以上。

代謝性疾病盛行率上升

隨著被診斷出患有糖尿病、肥胖、高血脂症、代謝症候群等代謝性疾病的患者不斷增加，需要治療的患者數量也不斷增加。許多代謝紊亂是慢性疾病，需要持續治療和管理。代謝性疾病種類繁多，治療所需的藥物也多種多樣，因此市場形勢也多種多樣。對治療此類疾病的藥物的需求不斷成長，直接支持了代謝治療市場的成長。

病患人數有限

代謝性疾病，尤其是罕見疾病和孤兒疾病，患者數量往往較少。這意味著與更常見的疾病相比，針對這些疾病的藥物的潛在市場是有限的。由於我們的患者人數較少，我們可能無法產生足夠的收益來證明代謝疾病治療的研發、臨床試驗和行銷所需的投資是合理的。由於市場規模較小，製藥公司可能在財務上難以收回藥物開發的高成本。這可能會導致患者缺乏有競爭力的選擇。

聯合治療日益受到關注

藥物的組合可以產生協同效應，其中藥物的組合效應大於其單獨效應的總合。這將改善臨床結果並更好地管理代謝疾病。代謝紊亂往往涉及複雜的生理過程，並受到多種因素的影響。聯合治療可以採用更全面的方法來解決這些複雜性，從而實現更有效的疾病管理。因此，其有效性、個體化藥物、擴大的治療選擇和最小化的副作用正在推動市場需求。

開發成本高

高開發成本可能會阻礙新陳代謝促進藥物市場的發展，因為製藥公司會更加規避風險，專注於更安全、既定的藥物開發途徑，而不是冒險創新代謝促進藥物。這是有性別的。此外，為了收回開發成本，製藥公司可能需要為改善新陳代謝的藥物設定更高的價格。這可能會限制患者的獲取，並對醫療保健系統提供負擔得起的治療構成挑戰。

COVID-19 的影響

COVID-19 大流行對代謝藥物市場產生了不同的影響，取決於特定藥物及其潛在疾病。由於封鎖、限制以及對前往醫療機構的擔憂，有些人推遲了就代謝疾病尋求醫療協助。這導致診斷和治療的延誤，可能影響新陳代謝改善藥物市場。另一方面，遠端醫療和遠端監測技術的引入可能會影響代謝症狀的管理方式並影響代謝藥物的處方模式。疫情過後市場正在反彈。

預計小分子藥物領域在預測期內將是最大的

由於其特異性的性質和優勢，小分子藥物領域預計將出現良好的成長。小分子藥物旨在與特定分子標靶相互作用，例如代謝過程中涉及的酶、受體和訊號途徑。這可以精確調節代謝途徑並治療糖尿病、高血脂症和肥胖等疾病。小分子藥物通常具有較低的製造成本，這使得它們對於患者和醫療保健系統來說具有成本效益。

預計糖尿病管理領域在預測期內將出現最高的年複合成長率

預計糖尿病管理領域在預測期內將出現最高的年複合成長率。代謝藥物有助於調節血糖值，在糖尿病管理中發揮重要作用。穩定血糖值，降低高血糖及其相關併發症的風險。改善血糖控制、降低併發症風險、提高生活品質和客製化治療計劃正在推動這一領域的成長。

比最大的地區

預計亞太地區在預測期內將佔據最大的市場佔有率。在中國、印度、日本和韓國等亞太國家，糖尿病、肥胖和心血管疾病等代謝性疾病的盛行率正在增加。這一趨勢是由久坐的生活方式、飲食變化和遺傳傾向等因素所驅動的。由於經濟成長和中等收入群體的不斷壯大，亞太地區許多國家正在增加醫療保健支出。亞太地區各國政府也正在採取措施應對日益嚴重的代謝紊亂負擔。

複合年複合成長率最高的地區：

預計歐洲在預測期內的年複合成長率最高。歐洲是製藥業中一個充滿活力的部門。歐洲代謝藥物市場競爭激烈，跨國製藥公司和本土製造商都扮演重要角色。諾和諾德、賽諾菲、Astra Zeneca和禮來等公司在該市場佔有重要地位。此外，歐洲還建立了孤兒疾病藥物的指定和核准框架，其中還包括某些罕見代謝疾病。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球代謝治療市場：依治療方法

  • 基材減少療法
  • 酵素替代療法
  • 小分子藥物
  • 其他治療方法

第6章 全球代謝治療市場：依藥物類別

  • 降血脂藥物
  • 抗糖尿病藥
  • 其他藥物類別

第7章 全球代謝治療市場：按配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球代謝治療市場：依應用分類

  • 糖尿病管理
  • 治療肥胖症
    • 處方藥
    • OTC（商店）補充劑
  • 高血脂症的治療
    • 他汀類藥物
    • 貝特類藥物系統
    • PCSK9抑制劑
  • 甲狀腺疾病
    • 甲狀腺機能低下症
    • 甲狀腺功能亢進症
  • 代謝症候群
    • 高血壓
    • 血脂異常症
    • 胰島素抗性
  • 罕見的代謝紊亂
    • 苯酮尿症 (PKU)
    • 高雪氏症
    • 法布瑞氏症
  • 其他用途

第9章 全球代謝治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Novartis AG
  • Merck & Co Inc.
  • Sanofi Genzyme
  • Amicus Therapeutics
  • AstraZeneca PLC
  • Horizon Pharma PLC
  • Shire PLC
  • Boehringer Ingelheim
  • BioMarin Pharmaceutical Inc.
  • Takeda Pharmaceuticals
  • GlaxoSmithKline PLC
  • Fuji Yakuhin
  • Mitsubishi Tanabe Pharma
  • Kowa Company
  • LG Life Science
  • Kythera Labs
Product Code: SMRC24319

According to Stratistics MRC, the Global Metabolism Drugs Market is accounted for $17.45 billion in 2023 and is expected to reach $30.85 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Metabolism drugs are medications designed to influence or regulate metabolic processes in the body. They are also known as metabolic modulators. They can have various benefits depending on the specific drug and the medical condition it is intended to treat. Metabolism drugs help the patient to improve cardiovascular health, enhance exercise performance, increase energy levels, reduce cholesterol levels and aids in weight management.

According to the World Health Organization (WHO), about 650 million people suffer from obesity in 2016 and is expected to increase more than four-fold times by 2030.

Market Dynamics:

Driver:

Rising prevalence of metabolic disorders

As the number of individuals diagnosed with metabolic disorders like diabetes, obesity, hyperlipidemia, and metabolic syndrome continues to rise, there is a larger patient population in need of treatment. Many metabolic disorders are chronic conditions that require ongoing treatment and management. The broad spectrum of metabolic disorders and the diverse range of drugs needed to treat them provide a wide market landscape. This increased demand for medications to manage these conditions directly supports the growth of the metabolism drugs market.

Restraint:

Limited patient populations

Metabolic disorders, especially rare or orphan diseases, often have a small patient population. This means that the potential market for drugs targeting these conditions is limited compared to more prevalent diseases. The small patient population may not generate enough revenue to justify the investment required for research, development, clinical trials, and marketing of a metabolism drug. The smaller market size can make it financially challenging for pharmaceutical companies to recoup the high costs of drug development. This can result in a lack of competitive options for patients.

Opportunity:

Growing focus on combination therapies

Combining drugs can result in synergistic effects, where the combined action of the drugs is greater than the sum of their individual effects. This can lead to improved clinical outcomes, allowing for better management of metabolic disorders. Metabolic disorders often involve complex physiological processes and may be influenced by multiple factors. Combination therapies allow for a more comprehensive approach to address these complexities, leading to more effective disease management. Thereby, their effectiveness, personalized medicines, expanded treatment options and minimization of side effects propels the market demand.

Threat:

High development costs

High development costs can hinder the metabolism drugs market as they can make pharmaceutical companies more risk-averse, leading them to focus on safer, more established drug development pathways rather than taking risks on innovative metabolism drugs. Also, in order to recoup their development costs, pharmaceutical companies may need to set higher prices for metabolism drugs. This can potentially limit access for patients and create challenges for healthcare systems in providing affordable treatments.

COVID-19 Impact

The COVID-19 pandemic has had varying impacts on the metabolism drugs market, depending on the specific drugs and the underlying conditions they treat. Due to lockdowns, restrictions, and concerns about visiting healthcare facilities, some individuals have delayed seeking medical attention for metabolic conditions. This lead to delayed diagnosis and treatment, potentially impacting the metabolism drugs market. On the other hand, the adoption of telemedicine and remote monitoring technologies have influenced how metabolic conditions were managed, potentially affecting prescription patterns for metabolism drugs. The market has been raised back in the post pandemic.

The small molecule drugs segment is expected to be the largest during the forecast period

The small molecule drugs segment is estimated to have a lucrative growth, due to their specific characteristics and benefits. They are designed to interact with specific molecular targets, such as enzymes, receptors, or signalling pathways, involved in metabolic processes. This allows for precise modulation of metabolic pathways, enabling the treatment of disorders like diabetes, hyperlipidemia, and obesity. Small molecule drugs are often less expensive to manufacture and can be more cost-effective for patients and healthcare systems.

The diabetes management segment is expected to have the highest CAGR during the forecast period

The diabetes management segment is anticipated to witness the highest CAGR growth during the forecast period. Metabolism drugs play a crucial role in diabetes management by helping to regulate blood sugar levels. They help to stabilize blood sugar levels, reducing the risk of hyperglycemia (high blood sugar) and its associated complications. It improves blood sugar control, reduces risk of complications, enhances quality of life and also customizes treatment plans which are thereby accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Asia-Pacific countries, including China, India, Japan, and South Korea, are witnessing a rising prevalence of metabolic disorders such as diabetes, obesity, and cardiovascular diseases. This trend is driven by factors like sedentary lifestyles, dietary changes, and genetic predispositions. With economic growth and a rising middle-class population, many countries in the Asia-Pacific region have seen an increase in healthcare expenditure. Also, governments in various Asia-Pacific have been taking measures to address the growing burden of metabolic disorders.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period. Europe is a dynamic sector within the pharmaceutical industry. The metabolism drugs market in Europe is competitive, with both multinational pharmaceutical companies and local manufacturers playing significant roles. Companies like Novo Nordisk, Sanofi, AstraZeneca, and Eli Lilly have a strong presence in this market. Also, Europe has a well-established framework for orphan drug designation and approval, which includes certain rare metabolic disorders.

Key players in the market

Some of the key players profiled in the Metabolism Drugs Market include: Novartis AG, Merck & Co Inc., Sanofi Genzyme, Amicus Therapeutics, AstraZeneca PLC, Horizon Pharma PLC, Shire PLC, Boehringer Ingelheim, BioMarin Pharmaceutical Inc., Takeda Pharmaceuticals, GlaxoSmithKline PLC, Fuji Yakuhin, Mitsubishi Tanabe Pharma, Kowa Company, LG Life Science, Kythera Labs and Eli Lilly.

Key Developments:

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

In October 2023, Sanofi launched speciality care growth products Beyfortus® and ALTUVIIIO® for the protection of all infants against RSV. Sanofi's profitability has improved as a result of the portfolio restructuring with these products.

In April 2023, Eli Lilly launched the diabetes and weight loss drugs Ozempic and Wegovy. Participants had lost about 21% of their body weight, which was unprecedented. The medications come at a time when obesity is the most prevalent chronic condition, affecting an estimated 650 million adults globally.

Therapy Types Covered:

  • Substrate Reduction Therapy
  • Enzyme Replacement Therapy
  • Small Molecule Drugs
  • Other Therapy Types

Drug Classes Covered:

  • Antihyperlipidemic Drugs
  • Antidiabetic Drugs
  • Other Drug Classes

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Diabetes Management
  • Obesity Treatment
  • Hyperlipidemia Management
  • Thyroid Disorders
  • Metabolic Syndrome
  • Rare Metabolic Disorders
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Metabolism Drugs Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Substrate Reduction Therapy
  • 5.3 Enzyme Replacement Therapy
  • 5.4 Small Molecule Drugs
  • 5.5 Other Therapy Types

6 Global Metabolism Drugs Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antihyperlipidemic Drugs
  • 6.3 Antidiabetic Drugs
  • 6.4 Other Drug Classes

7 Global Metabolism Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Metabolism Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Diabetes Management
  • 8.3 Obesity Treatment
    • 8.3.1 Prescription Medications
    • 8.3.2 OTC (Over-the-Counter) Supplements
  • 8.4 Hyperlipidemia Management
    • 8.4.1 Statins
    • 8.4.2 Fibrates
    • 8.4.3 PCSK9 Inhibitors
  • 8.5 Thyroid Disorders
    • 8.5.1 Hypothyroidism
    • 8.5.2 Hyperthyroidism
  • 8.6 Metabolic Syndrome
    • 8.6.1 Hypertension
    • 8.6.2 Dyslipidemia
    • 8.6.3 Insulin Resistance
  • 8.8 Rare Metabolic Disorders
    • 8.8.1 Phenylketonuria (PKU)
    • 8.8.2 Gaucher Disease
    • 8.8.3 Fabry Disease
  • 8.8 Other Applications

9 Global Metabolism Drugs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 Merck & Co Inc.
  • 11.3 Sanofi Genzyme
  • 11.4 Amicus Therapeutics
  • 11.5 AstraZeneca PLC
  • 11.6 Horizon Pharma PLC
  • 11.7 Shire PLC
  • 11.8 Boehringer Ingelheim
  • 11.9 BioMarin Pharmaceutical Inc.
  • 11.10 Takeda Pharmaceuticals
  • 11.11 GlaxoSmithKline PLC
  • 11.12 Fuji Yakuhin
  • 11.13 Mitsubishi Tanabe Pharma
  • 11.14 Kowa Company
  • 11.15 LG Life Science
  • 11.16 Kythera Labs

List of Tables

  • Table 1 Global Metabolism Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Metabolism Drugs Market Outlook, By Therapy Type (2021-2030) ($MN)
  • Table 3 Global Metabolism Drugs Market Outlook, By Substrate Reduction Therapy (2021-2030) ($MN)
  • Table 4 Global Metabolism Drugs Market Outlook, By Enzyme Replacement Therapy (2021-2030) ($MN)
  • Table 5 Global Metabolism Drugs Market Outlook, By Small Molecule Drugs (2021-2030) ($MN)
  • Table 6 Global Metabolism Drugs Market Outlook, By Other Therapy Types (2021-2030) ($MN)
  • Table 7 Global Metabolism Drugs Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 8 Global Metabolism Drugs Market Outlook, By Antihyperlipidemic Drugs (2021-2030) ($MN)
  • Table 9 Global Metabolism Drugs Market Outlook, By Antidiabetic Drugs (2021-2030) ($MN)
  • Table 10 Global Metabolism Drugs Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 11 Global Metabolism Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 12 Global Metabolism Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 13 Global Metabolism Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Metabolism Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 15 Global Metabolism Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 16 Global Metabolism Drugs Market Outlook, By Diabetes Management (2021-2030) ($MN)
  • Table 17 Global Metabolism Drugs Market Outlook, By Obesity Treatment (2021-2030) ($MN)
  • Table 18 Global Metabolism Drugs Market Outlook, By Prescription Medications (2021-2030) ($MN)
  • Table 19 Global Metabolism Drugs Market Outlook, By OTC (Over-the-Counter) Supplements (2021-2030) ($MN)
  • Table 20 Global Metabolism Drugs Market Outlook, By Hyperlipidemia Management (2021-2030) ($MN)
  • Table 21 Global Metabolism Drugs Market Outlook, By Statins (2021-2030) ($MN)
  • Table 22 Global Metabolism Drugs Market Outlook, By Fibrates (2021-2030) ($MN)
  • Table 23 Global Metabolism Drugs Market Outlook, By PCSK9 Inhibitors (2021-2030) ($MN)
  • Table 24 Global Metabolism Drugs Market Outlook, By Thyroid Disorders (2021-2030) ($MN)
  • Table 25 Global Metabolism Drugs Market Outlook, By Hypothyroidism (2021-2030) ($MN)
  • Table 26 Global Metabolism Drugs Market Outlook, By Hyperthyroidism (2021-2030) ($MN)
  • Table 27 Global Metabolism Drugs Market Outlook, By Metabolic Syndrome (2021-2030) ($MN)
  • Table 28 Global Metabolism Drugs Market Outlook, By Hypertension (2021-2030) ($MN)
  • Table 29 Global Metabolism Drugs Market Outlook, By Dyslipidemia (2021-2030) ($MN)
  • Table 30 Global Metabolism Drugs Market Outlook, By Insulin Resistance (2021-2030) ($MN)
  • Table 31 Global Metabolism Drugs Market Outlook, By Rare Metabolic Disorders (2021-2030) ($MN)
  • Table 32 Global Metabolism Drugs Market Outlook, By Phenylketonuria (PKU) (2021-2030) ($MN)
  • Table 33 Global Metabolism Drugs Market Outlook, By Gaucher Disease (2021-2030) ($MN)
  • Table 34 Global Metabolism Drugs Market Outlook, By Fabry Disease (2021-2030) ($MN)
  • Table 35 Global Metabolism Drugs Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.